Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium's metabolism is constrained by the intracellular environment.
VanderVen BC, Fahey RJ, Lee W, Liu Y, Abramovitch RB, Memmott C, Crowe AM, Eltis LD, Perola E, Deininger DD, Wang T, Locher CP, Russell DG. VanderVen BC, et al. Among authors: deininger dd. PLoS Pathog. 2015 Feb 12;11(2):e1004679. doi: 10.1371/journal.ppat.1004679. eCollection 2015 Feb. PLoS Pathog. 2015. PMID: 25675247 Free PMC article.
2-N-Arylthiazole inhibitors of Mycobacterium tuberculosis.
Clark MP, Wang T, Perola E, Deininger DD, Zuccola HJ, Jones SM, Gao H, VanderVen BC, Russell DG, Shoen CM, Cynamon MH, Thomson JA, Locher CP. Clark MP, et al. Among authors: deininger dd. Bioorg Med Chem Lett. 2017 Sep 1;27(17):3987-3991. doi: 10.1016/j.bmcl.2017.07.067. Epub 2017 Jul 27. Bioorg Med Chem Lett. 2017. PMID: 28778468
Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy.
Perola E, Stamos D, Grillot AL, Ronkin S, Wang T, LeTiran A, Tang Q, Deininger DD, Liao Y, Tian SK, Drumm JE, Nicolau DP, Tessier PR, Mani N, Grossman TH, Charifson PS. Perola E, et al. Among authors: deininger dd. Bioorg Med Chem Lett. 2014 May 1;24(9):2177-81. doi: 10.1016/j.bmcl.2014.03.022. Epub 2014 Mar 19. Bioorg Med Chem Lett. 2014. PMID: 24685546
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
Charifson PS, Grillot AL, Grossman TH, Parsons JD, Badia M, Bellon S, Deininger DD, Drumm JE, Gross CH, LeTiran A, Liao Y, Mani N, Nicolau DP, Perola E, Ronkin S, Shannon D, Swenson LL, Tang Q, Tessier PR, Tian SK, Trudeau M, Wang T, Wei Y, Zhang H, Stamos D. Charifson PS, et al. Among authors: deininger dd. J Med Chem. 2008 Sep 11;51(17):5243-63. doi: 10.1021/jm800318d. Epub 2008 Aug 9. J Med Chem. 2008. PMID: 18690678
Design and synthesis of novel conformationally restricted HIV protease inhibitors.
Salituro FG, Baker CT, Court JJ, Deininger DD, Kim EE, Li B, Novak PM, Rao BG, Pazhanisamy S, Porter MD, Schairer WC, Tung RD. Salituro FG, et al. Among authors: deininger dd. Bioorg Med Chem Lett. 1998 Dec 15;8(24):3637-42. doi: 10.1016/s0960-894x(98)00670-2. Bioorg Med Chem Lett. 1998. PMID: 9934485
Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS).
Come JH, Collier PN, Henderson JA, Pierce AC, Davies RJ, Le Tiran A, O'Dowd H, Bandarage UK, Cao J, Deininger D, Grey R, Krueger EB, Lowe DB, Liang J, Liao Y, Messersmith D, Nanthakumar S, Sizensky E, Wang J, Xu J, Chin EY, Damagnez V, Doran JD, Dworakowski W, Griffith JP, Jacobs MD, Khare-Pandit S, Mahajan S, Moody CS, Aronov AM. Come JH, et al. J Med Chem. 2018 Jun 28;61(12):5245-5256. doi: 10.1021/acs.jmedchem.8b00085. Epub 2018 Jun 14. J Med Chem. 2018. PMID: 29847724
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors.
Tang Q, Aronov AM, Deininger DD, Giroux S, Lauffer DJ, Li P, Liang J, McGinty K, Ronkin S, Swett R, Waal N, Boucher D, Ford PJ, Moody CS. Tang Q, et al. Among authors: deininger dd. ACS Med Chem Lett. 2021 May 24;12(6):955-960. doi: 10.1021/acsmedchemlett.1c00094. eCollection 2021 Jun 10. ACS Med Chem Lett. 2021. PMID: 34141080 Free PMC article.
Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
Perni RB, Pitlik J, Britt SD, Court JJ, Courtney LF, Deininger DD, Farmer LJ, Gates CA, Harbeson SL, Levin RB, Lin C, Lin K, Moon YC, Luong YP, O'Malley ET, Rao BG, Thomson JA, Tung RD, Van Drie JH, Wei Y. Perni RB, et al. Among authors: deininger dd. Bioorg Med Chem Lett. 2004 Mar 22;14(6):1441-6. doi: 10.1016/j.bmcl.2004.01.022. Bioorg Med Chem Lett. 2004. PMID: 15006379
Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants.
Perni RB, Britt SD, Court JC, Courtney LF, Deininger DD, Farmer LJ, Gates CA, Harbeson SL, Kim JL, Landro JA, Levin RB, Luong YP, O'Malley ET, Pitlik J, Rao BG, Schairer WC, Thomson JA, Tung RD, Van Drie JH, Wei Y. Perni RB, et al. Among authors: deininger dd. Bioorg Med Chem Lett. 2003 Nov 17;13(22):4059-63. doi: 10.1016/j.bmcl.2003.08.050. Bioorg Med Chem Lett. 2003. PMID: 14592508
14 results